Outline for PowerPoint Presentation: "Cannabis as an Opioid Alternative" (For Cannabiziac)

1. Introduction to the Opioid Crisis

• Overview of opioid crisis → 91,799 opioid overdose deaths in the US in 2020 (CDC, 2022).

• Chronic pain prevalence → 20.4% of U.S. adults report chronic pain (CDC, 2021).

• Current treatment paradigm → opioids as first-line therapy for moderate to severe pain.

2. Cannabis: A Potential Alternative for Pain Management

• Mechanism of action of cannabis vs. opioids.

  • Opioids: μ-opioid receptor (MOR) agonists → G-protein activation ↓ adenylate cyclase activity ↓ cAMP production → K+ efflux ↑, Ca2+ influx ↓ → neuronal hyperpolarization → pain signal transmission ↓ (Pradhan et al., 2020).

  • Cannabis: Δ9-THC → CB1, CB2 receptor agonism → ↓ neurotransmitter release → pain signal transmission ↓ (Huang et al., 2019).

• Cannabis does not cause respiratory depression (↑ safety profile) vs. opioids (down arrow respiratory drive).

3. Pharmacological Differences: Opioids vs. Cannabis

• Opioids:

  • High addiction potential → ↑ dopamine in nucleus accumbens → reward pathway activation.

  • Tolerance development → MOR desensitization → increased dosage requirement over time.

  • Long-term opioid use → ↑ risk of hyperalgesia (Mao et al., 2020).

• Cannabis:

  • Lower addiction risk → CB1 receptor agonism → dopamine release (↓ compared to opioids).

  • Lesser tolerance development (Ahn et al., 2019).

  • Δ9-THC & CBD ↓ pain perception without strong reward pathway activation.

4. Clinical Evidence: Efficacy in Pain Management

• Meta-analysis (Whiting et al., 2015) → 37 RCTs: Cannabinoids effective for chronic pain (average pain intensity ↓ by 30%) in 29% of participants vs. 26% with placebo.

• Opioid use ↓ by 64% among chronic pain patients using medical cannabis (Boehnke et al., 2016).

• Cannabis adjunct to opioids → opioid-sparing effect ↑ (Vyas et al., 2018).

5. Molecular Pathways: Cannabis vs. Opioids

• CB1 receptor activation → ↓ GABA, glutamate release → ↓ nociceptive transmission (Chagas et al., 2019).

• Opioid pathway → MOR activation → β-arrestin recruitment ↑ → respiratory depression risk ↑ (Laugwitz et al., 2020).

• Cannabis: Limited β-arrestin recruitment (↓ adverse effects compared to opioids) → safer therapeutic window.

6. Safety Profile & Side Effects

• Opioids:

  • High risk of overdose → respiratory depression ↑, addiction risk ↑.

  • Opioid-induced constipation (OIC) → affects up to 60% of chronic opioid users.

• Cannabis:

  • No lethal dose established (Greydanus et al., 2019).

  • Common side effects: Dry mouth, dizziness (mild compared to opioids).

7. Public Health Implications

• States with legalized medical cannabis → ↓ 25% opioid overdose mortality (Bachhuber et al., 2014).

• Decrease in opioid prescriptions in states with medical cannabis programs → opioid prescription rates ↓ by 6% (Wen & Hockenberry, 2018).

• Federal scheduling limitations for cannabis research ↓ slow progression of policy reform.

8. Regulatory and Policy Considerations

• Opioid regulation → Stringent opioid prescription policies after CDC guidelines (2016).

• Cannabis legalization → 38 states with medical cannabis laws → inconsistent regulatory framework.

• Policy reform needed to align with growing clinical evidence supporting cannabis as a safer alternative.

9. Recommendations for Physicians and Healthcare Providers

• Education and awareness about cannabis as an adjunct or alternative to opioid therapy.

• Consideration of patient-specific factors (e.g., history of substance abuse, comorbidities).

• Monitoring and dosing guidance for cannabis therapy → CB1 tolerance over time ↓ need for opioid dose escalation.

10. Conclusion

• Cannabis presents a viable alternative to opioids in chronic pain management, with a safer side effect profile.

• Further research needed on long-term effects and standardized dosing protocols.

• Clinical and policy-level collaboration critical to integrate cannabis into mainstream pain management practices.

Peer-Reviewed References

1. Pradhan, A. A., et al. (2020). "The role of δ-opioid receptors in pain control and their potential as a therapeutic target for opioid use disorders." Neuropharmacology.

2. Huang, S. M., et al. (2019). "Cannabinoid Receptor Signaling and the Regulation of Pain." Pain.

3. Boehnke, K. F., et al. (2016). "Medical Cannabis Use Is Associated With Decreased Opioid Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain." Journal of Pain.

4. Whiting, P. F., et al. (2015). "Cannabinoids for Medical Use: A Systematic Review and Meta-analysis." JAMA.

5. Wen, H., & Hockenberry, J. M. (2018). "Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees." JAMA Internal Medicine.

6. Bachhuber, M. A., et al. (2014). "Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010." JAMA Internal Medicine.

7. Greydanus, D. E., et al. (2019). "Marijuana: Current Concepts." Frontiers in Public Health.

8. Mao, J., et al. (2020). "Opioid-Induced Hyperalgesia: Implications for Clinical Management." Pain Physician.

9. Vyas, M. B., et al. (2018). "The Use of Cannabis in Response to the Opioid Crisis: A Review of the Literature." Nursing Outlook.

CONTACT US SO WE CAN HELP YOUR 

FACILITY | GROUP | ORGANIZATION

Email: DrTerelNewton@gmail.com    

Text: 321-987-9008 

Improved Intake Form for Consulting Services

Business Information

• Business Name: __________________________

• Industry/Field: __________________________

• Contact Person: __________________________

• Position/Title: __________________________

• Business Address: __________________________

• Phone Number: __________________________

• Email Address: __________________________

• Preferred Method of Contact (Phone/Email): __________

Project Details

• Project Title/Name (if applicable): __________________________

• Briefly describe your current educational and/or health management programs (if any):

  • 
    

• What are your specific goals for this consulting project?

  • 
    

• Who is your target audience? (Employees, Management, Community, etc.)

  • 
    

• What are your expected outcomes or desired results from this project?

  • 
    

Project Scope and Requirements

• What specific areas of focus are you most interested in? (e.g., Chronic Pain Management, Opioid Alternatives, Employee Wellness)

  • 
    

• What are the primary challenges or concerns you're facing in relation to these areas?

  • 
    

• What is your timeline for completing this project?

  • Start Date: __________ End Date: __________

• What is your budget for this project?

  • Available Budget: $______________

• What format of deliverables do you prefer? (Workshops, Webinars, Documentation, etc.)

  • 
    

Additional Information

• Have you previously implemented any initiatives or programs related to chronic pain management or opioid alternatives?

  • 
    

• Are there any key stakeholders or partners involved in this project?

  • 
    

• How did you hear about our consulting services?

  • 
    

Consent and Confirmation

• By submitting this form, you consent to being contacted and for your information to be used for the consulting project.

  • [ ] Yes, I consent.

  • [ ] No, I do not consent.

Signature: __________________________ Date: __________

Submit Button (for online forms) or Instruction to Return Completed Form (for paper forms)